Treating Breast Cancer

2006/12/01 07:51

Press Release from:

Asset Chemist

Since Herceptin received regulatory approval in May 2006, it as courted controversy in the UK, with patients taking PCTs to court to be able to get the drug prescribed on the NHS.

Herceptin is the first humanized antibody approved for the treatment of HER2-positive metastatic breast cancer. Herceptin is designed to target and block the function of HER2 protein overexpression.
Research has shown that HER2-positive breast cancer is a more aggressive disease with a greater likelihood of recurrence, a poorer prognosis, and a decreased chance of survival compared with

HER2-negative breast cancer.

Herceptin, also known as trastuzumab, works by targeting the HER2 protein, which can fuel growth of breast tumours in women with HER2 positive breast cancer.
This kind of cancer accounts for about 20% of all breast cancer cases.

Asset Chemist has now made it available on its Online Pharmacy portal, rxchemist.co.uk. rxchemist.co.uk, caters for both private and UK NHS patients, delivering products via registered mail.